All News

Katherine Tromp, PharmD, interim dean at Northeast Ohio Medical University College of Pharmacy, discusses how pharmacists can help prevent heart disease in women.

Over 20 years since skin of color dermatology was introduced, researchers explored advancements and what is yet to come in the future.

The drug is approved for the short-term treatment of acute repetitive seizures, also known as seizure clusters, which differ from a patient’s normal seizure pattern.

Thanks to widespread vaccination, the country nearly eliminated measles, maintaining only about 63 cases per year between 2000 and 2019.

Pain expert Mark Garofoli, PharmD, BCGP, CPE, CTTS, discussed the pharmacist’s role in managing patients’ use of OTC pain relief products.

At AAP 2025, Melanie Maxwell, president of AlignRx, discussed the intent, benefits and consequences of the IRA.

On behalf of 39 state and territory attorneys general, the National Association of Attorneys General issued a letter to Congress regarding major PBMs’ conflicts of interest.

Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discusses effective strategies for balancing excellent patient care with strict regulations surrounding controlled substances.

David Blair, CEO of LucyRx, joined Drug Topics to discuss the initiatives his company is conducting in support of a struggling pharmacy profession.

The FDA approved adalimumab-aaty in May 2023 for 8 indications, including rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.

One asymptomatic patient did experience drug-induced liver injury that was resolved after discontinuation of danuglipron.

At AAP 2025, Douglas Hoey, CEO of NCPA, discussed the possibility of PBM reform under the new administration and his take on Optum Rx’s plans to introduce a cost-plus reimbursement model.

In a telephone audit, researchers attempted to quantify the frequency of patient barriers when looking to purchase sterile syringes from community pharmacies for over-the-counter use.

First-in-class brensocatib has the potential to be the first approved treatment for bronchiectasis.

With transitions of care inclusive of multiple health care settings, each provider must play a specific role to ensure overall improved patient outcomes.

Researchers explored TikTok’s role in the dissemination of information regarding isotretinoin and its users.

At AAP 2025, Ron Friedman discussed best practices for responding to a DEA inspection, how to identify any red flags, and best practices for dispensing.

However, patients should still be monitored for potential serious adverse effects, as investigators identified potential new concerns.

Furthermore, C-reactive protein has greater prognosis for lung cancer, colorectal cancer, and ovarian cancer.

Allergy season is here. Help your patients tackle sneezing, itching, and congestion with this guide to the best OTC treatments.

DeLon Canterbury, PharmD, BCGP, discusses how his career journey led him to medication deprescribing and advocating for older adults.

At the American Associated Pharmacies Annual Conference, Douglas Hoey, RPh, MBA, discussed what needs to change in the program so that it does not hurt pharmacies and patients.

A conversation with Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, at the American Associated Pharmacies 2025 Annual Conference.

Collaborative practice agreements enable pharmacists to leverage their expertise beyond traditional dispensing, but barriers continue to limit their implementation.

Researchers explored the association of a pneumococcal polysaccharide vaccine booster and health care utilization in children with sinusitis and low pneumococcal antibody titers.

Dae Lee, PharmD, Esq, CPBS, discusses the legal and billing challenges hindering pharmacy practices and opportunities to overcome them.

David Blair, CEO of LucyRx, discusses the common challenges his clients face and how his company’s innovative model can help them overcome financial hurdles.

A conversation with Scott Biggs and Greg Mitchell at the American Associated Pharmacies 2025 Annual Conference.

The drug is also approved for adults with chronic inflammatory demyelinating polyneuropathy.

The new approval is the first nonopioid option for moderate to severe acute pain in adults.